Yunnan Province Cancer Hospital /ID# 272331

Kunming, Yunnan 650106

1 studies enrolling now · 1 studies all time

What they study most

Non Small Cell Lung Carcinoma

Studies at this site

• Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations — Recruiting now